NEW YORK—(BUSINESS WIRE)—Forest Laboratories Holdings Limited, a wholly owned subsidiary of
Forest Laboratories, Inc. (NYSE:FRX) today announced that the company is acquiring exclusive rights
in the United States for Saphris® (asenapine) sublingual tablets, a treatment for adult
patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly
owned subsidiary of Merck & Co., Inc. (NYSE:MRK).